HER2Bi-Armed Activated T Cells clinical trials
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How each study uses HER2Bi-Armed Activated T Cells is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2010 (2)
| Year | Studies |
|---|---|
| 2010 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 5
Barbara Ann Karmanos Cancer Institute (4) · Yi Miao (1)
Often tested with
Tested in the same studies.
Aldesleukin (2) · Cyclophosphamide (1) · Interleukin-2 (1) · Sargramostim (1)
Studies
Open first, then newest update. How each study uses HER2Bi-Armed Activated T Cells is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate CancerCompletedPhase 2Barbara Ann Karmanos Cancer InstituteNCT03406858Written as HER2Bi-Armed Activated T Cells
- Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing SurgeryTerminatedPhase 2Barbara Ann Karmanos Cancer InstituteNCT01147016Written as HER2Bi-armed activated T cells
- Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast CancerTerminatedPhase 2Barbara Ann Karmanos Cancer InstituteNCT01022138Written as HER2Bi-armed activated T cells
- Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or RecurrentWithdrawnPhase 1Barbara Ann Karmanos Cancer InstituteNCT02470559Written as HER2Bi-Armed Activated T Cells
- T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive SystemStatus unknownPhase 1Yi MiaoNCT02662348Written as HER2Bi-Armed T Cells